ASC Depletion Synergizes with Cisplatin in a Breast Cancer Metastasis Model
(A) Orthotopic 4T1 tumor growth in BALB/C mice injected with PBS, 0.75 mg/kg D-CAN, 0.6 mg/kg cisplatin (C 0.6), 3 mg/kg cisplatin (C 3.0), or 0.75 mg/kg D-CAN + 0.6 mg/kg cisplatin (N = 5 to 6/group). Injections (3/week) started when tumors reached 0.1 cm (day 1). (Right plot) Final tumor volume; ∗p < 0.05 (unpaired Student’s t test) for the C 0.6 versus C 0.6 + D-CAN group. (B) Kaplan-Meier curves showing percent survival of mice from (A). (C) Representative images of lungs from mice in (A) resected on day 20. Arrows, metastases. (D) H&E stainings of lungs from mice in (A) resected on day 20 post-tumor grafting. (E) Metastatic area determined with NIH ImageJ software by analysis of 10× fields and mean number of metastases/lung quantified through analysis of sections in (D). ∗p < 0.05 (unpaired Student’s t test). Scale bar, 250 μm. See also Figure S2.